Autism Spectrum DisorderPhase 2NCT03202303
Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)
A Phase 2 study testing Cannabidivarin in people with Autism Spectrum Disorder, run by Montefiore Medical Center at 2 sites in United States.
Trial summary
This trial aims to study the efficacy and safety of cannabidivarin (CBDV) in children with ASD. Read more about this study
- Who is it for?
- Ages 5 to 18 years
- Conditions the study is for
- Autism Spectrum Disorder
- What is being tested?
- Cannabidivarin
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- 2 sitesUnited States
- Study dates
- 12 Apr 2019to 30 Jun 2026
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Male or Female pediatric outpatients aged between and including ages 5 to 18. Diagnosis of Autism Spectrum Disorder (ASD) confirmed by the ADOS-2 and DSM-5 criteria.*During special circumstances (e.g. COVID-19 pandemic) where the ADOS-2 cannot be performed due to site restrictions (e.g. mandatory use of face masks), eligibility can be confirmed using the Autism Diagnostic Interview, Revised (ADI-R)
- Aberrant Behavior Checklist (ABC) - Irritability Subscale (ABC-I) score of 18 or greater at screening visit.
- Social Responsiveness Scale (SRS) score of 66T or higher at screening visit.
- Clinical Global Impression Scale - Severity (CGI-S) score of 4 or higher at screening.
- Stable pharmacologic, educational, behavioral and/or dietary interventions for 4 weeks prior to randomization and for the duration of the study.
- Physical exam and laboratory results that are within normal range for individuals with ASD.
- Presence of a parent/caregiver/guardian that is able to consent for their participation and complete assessments regarding the child's development and behavior throughout the study. Child Assent will be obtained if the subject is 7 years of age or older and has the mental capacity to understand and sign a written assent form and/or give verbal assent.
Who cannot join
- Exposure to any investigational agent in the 30 days prior to randomization.
- Prior chronic treatment with CBD, CBDV or an endocannabinoid treatment.
- Positive testing for THC or other drugs of abuse via urine testing at the screening visit or baseline visits upon repeat confirmation testing.
- Recent history of drug abuse including marijuana/cannabis use in the past 3 months.
- Diagnosis of a known genetic disorder (ie. Prader-Willi Syndrome, Angelman Syndrome etc.).
- A primary psychiatric diagnosis other than ASD, including bipolar disorder, psychosis, schizophrenia, Post-Traumatic Stress Disorder (PTSD) or Major Depressive Disorder (MDD). These patients will be excluded due to potential confounding results.
Show all 13Show fewer
- A medical condition that severely impacts the subject's ability to participate in the study, interferes with the conduct of the study, confounds interpretation of study results or endangers the subject's well-being.
- A known diagnosis of Rett Syndrome or Childhood Disintegrative Disorder, or marked sensory impairment such as deafness or blindness.
- Subjects who have had changes in allied health therapies, behavioral or educational interventions within four weeks prior to randomization other than those associated with school holidays.
- Subjects who have had changes in medications or medication doses within four weeks of randomization. Renal, pancreatic, or hematologic dysfunction as evidenced by values above upper limits of normal for BUN/creatinine, or values twice the upper limit of normal for serum lipase and amylase, platelets <80,000 /mcL, or WBC<3.0 103 /mcL
- Liver dysfunction manifested by > 2 X UNL values of AST or ALT
- ECG abnormality at baseline screening or clinically significant postural drop in systolic blood pressure at screening. If the initial screening ECG show a QTcB of greater than 460 msec, then 2 additional ECGs will be conducted in the same sitting, 5 minutes apart. If not recognized at screening, then a full triplicate repeat showing an average QTcB of 460 msec or less to meet all inclusion/exclusion criteria. Female subjects who are pregnant will be excluded from the study. If a female subject is able to become pregnant, she will be given a serum pregnancy test before entry into the study. Female subjects will be informed not to become pregnant while taking CBDV. Female subjects must tell the investigator and consult an obstetrician or maternal-fetal specialist if they become pregnant during the study.
- Known allergy to sesame oil
Trial locations and contacts
2 sites in 1 country.
United States2 sites
New York University (NYU) Langone
New York, New York, 10016
Montefiore Medical Center
The Bronx, New York, 10467
About this study
This trial aims to study the efficacy and safety of cannabidivarin (CBDV) in children with ASD.
Read the detailed description
There is a clear unmet need for new therapeutics to treat irritability in children with ASD that do not have the metabolic and weight adverse event profiles of the currently approved treatments. Cannabidivarin (CBDV) is a nonpsychoactive phytocannabinoid and a safe variant of Cannabidiol (CBD). It has no appreciable tetrahydrocannabinol (THC) [less than 0.01%], has been shown to have no impact on weight or metabolism, and improves both social and cognitive functioning in animal models of idiopathic and syndromal autism (Fragile X, Rett Syndrome, Angelman Syndrome). The CDC currently estimates 1 in 59 children have ASD. ASD is characterized by deficits in social communication, irritability, repetitive behaviors, impulsivity, temper tantrums, and high caregiver burden. Currently, the only FDA-approved medications for symptoms of ASD are aripiprazole and risperidone, both of which are indicated for irritability in pediatric ASD. These medications are effective but are associated with considerable side effects with long term treatment in this chronic developmental disorder, including weight gain, metabolic syndrome and the risk of type 2 diabetes, prolactin elevation and growth of breast tissue, extrapyramidal symptoms and the risk of tardive dyskinesia. The anticonvulsant divalproex sodium (valproate/VPA) also significantly reduces irritability and repetitive behaviors in individuals with ASD. Although VPA is efficacious for pediatric epilepsy and some symptoms of ASD, it also has significant side effects, including weight gain, sedation and nausea. CBDV, like VPA, is effective in the treatment of pediatric epilepsy, and ASD mouse models demonstrate potential mechanisms for treatment with CBDV, including potential therapeutic effects on repetitive behaviors, irritability, sociability, and quality of life, and the capacity to reduce inflammation. This study aims to examine the efficacy and safety of cannabidivarin (CBDV) with a primary aim of studying its effect on irritability in children with ASD.
STUDY DESIGN: This is a 12-week randomized, double-blind study of CBDV vs. placebo in 100 child and adolescent subjects aged 5 to 18 years with a diagnosis of ASD.
- Conditions
- Autism Spectrum Disorder
- Being tested
- Cannabidivarin, Matched Placebo
- Keywords
- Autism, Irritability, Cannabinoids
- Medical subject headings
- Autism Spectrum Disorder, Autistic Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CannabidivarinDrug
Also called CBDV
Weight-based dosing of 10 mg/kg/day of CBDV
Matched PlaceboDrug
Also called Placebo
Weight-based dosing of 10 mg/kg/day of placebo
| Study group | Role | What they receive |
|---|---|---|
| Cannabidivarin (CBDV) | Experimental | Weight-based dosing of 10 mg/kg/day of CBDV for 12 weeks Receives: Drug: Cannabidivarin |
| Matched Placebo | Placebo comparator | Weight-based dosing of 10 mg/kg/day of placebo for 12 weeks Receives: Drug: Matched Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Aberrant Behavior Checklist-Irritability (ABC-I) Subscale
Change in aberrant behavior from baseline will be assessed using the irritability subscale of the ABC. The ABC is an informative rating instrument that was empirically derived by principal component analysis to measure behavior in those with developmental disability and autism spectrum disorder (ASD). The ABC-I will be completed by any adult who knows the patient well, such as a parent/caregiver. The ABC-I subscale consists of 15 items that address the presence of aggression, tantrums, and/or self-injury. Scores for each item on the subscale range from 0 (no problem at all) to 3 (problem is severe in degree), yielding an overall possible score for the subscale from 0-45, such that higher scores are indicative of increased severity of irritability. Scores will be summarized by study arm using basic descriptive statistics.
Measured: Change from Baseline to Week 12 (Change over 12 weeks)
Secondary outcomes (6)
Repetitive Behavior Scale-Revised (RBS-R)
Change in repetitive behavior from baseline will be assessed using the RBS-R, a 43-item self-report instrument that is used to measure the breadth of repetitive behaviors specific to autism spectrum disorder (ASD) symptomatology. The 43 items encompass 6 behavioral subscales including: Stereotypic (6 items); Self-injurious (8 items); Compulsive (8 items); Ritualistic (6 items); Sameness (11 items); and Restricted Behavior (4 items). A list of behaviors will be presented and the parent will be asked to choose a score that best describes how much of a problem the behavior has been over the last month. Behaviors are rated on a 4-point scale: 0 (behavior does not occur), 1 (behavior occurs and is a mild problem), 2 (behavior occurs and is a moderate problem) and 3 (behavior occurs and is a severe problem). Higher scores reflect increased severity of repetitive behavior for that scale. Scores for each of the 6 subscales will be summarized by arm using basic descriptive statistics.
Measured: Change in RBS-R from Baseline to Week 12 (Change over 12 weeks)
Montefiore Einstein Rigidity Scale-Revised (MERS-R)
Change in rigidity from baseline will be assessed using the MERS-R. MERS-R is designed to assess three domains of rigid behavior in children (and adults) with ASD: Behavioral Rigidity (e.g., insistence on sameness, things must be done his/her way, etc.); Cognitive Rigidity (e.g., special interests, inflexible adherence to rules, etc.); and Protest (in response to deviation from rigidity; e.g., verbal objection, tantrum, physical aggression). MERS-R is a clinician-rated scale and will only be completed only for subjects who display rigid behaviors at baseline, and study visits during week 4, week 8, and week 12. The MERS-R consists of 43 items. Each item is scored based on a 4-point scale ranging from 0 (no problem) to 3 (severe problem) for rigid behaviors displayed over the past month, yielding an overall MERS-R score of 0-129. Higher scores are associated with more severe rigidity. Scores will be summarized by study arm using basic descriptive statistics.
Measured: Change in MERS-R from Baseline to Week 12 (Change over 12 weeks)
Aberrant Behavior Checklist-Social Withdrawal (ABC-SW) Subscale
Change in aberrant behavior from baseline will also be evaluated using the Social Withdrawal subscale of the Aberrant Behavior Checklist (ABC). The ABC is an informant rating instrument that measures behavior in individuals with developmental disability and ASD. The ABC-SW scale measures behavior using a 4-point severity scale, ranging from 0-3, where parents rate aberrant behaviors as 0 = no problem at all, 1 = behavior is a problem but in a slight degree, 2 = problem is moderately serious, and 3 = problem is severe in degree, such that higher scores are associated with increased severity of social withdrawal, for an overall possible score of 0-48. Scores will be summarized by study arm using basic descriptive statistics.
Measured: Change in ABC-SW from Baseline to Week 12 (Change over 12 weeks)
Pediatric Quality of Life Inventory (PedsQL) Family Impact Module
Change in quality of life is assessed using the PedsQL family impact module, a 36-item self-report caregiver form used to measure caregiver functioning. PedsQL encompasses 6 scales: Physical Functioning (6 items), Emotional Functioning (5 items), Social Functioning (4 items), Cognitive Functioning (5 items), Communication (3 items), Worry (5 items) and 2 scales measuring caregiver-reported family functioning: Daily Activities (3 items) and Family Relationships (5 items). Each item is scored using a 5-point scale ranging from 0 (never a problem) to 4 (always a problem). Items are then reverse-scored and transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0), such that higher scores indicate better functioning (less negative impact). Scale Scores are computed as the sum of the items divided by the number of items answered (to account for missing data). If >50% of the items in the scale are missing, a scale score is not computed. Scores will be summarized by study arm.
Measured: Change in PedsQL from Baseline to Week 12 (Change over 12 weeks)
Vineland Adaptive Behavior Scale, Third Edition (VABS-3)
Change in adaptive behavior from baseline will be assessed using the VABS-3. The VABS-3 is an instrument that measures adaptive behavior across 5 domains: communication, daily living skills, socialization, motor skills, and maladaptive behavior of individuals with developmental disabilities. The Survey Interview Form (semi-structured interview) will be administered to a participant's reliable caregiver in this study, during which the interviewer will ask the caregiver open ended questions relating to the subject's activities and behavior. Scoring involves assigning points (0, 1, or 2) to each item based on the responses to the questions. These scores are then compared to normative data to determine the individual's standing relative to peers. Higher scores are generally indicative of better adaptive behavior. Scores will be summarized by study arm using basic descriptive statistics.
Measured: Change in VABS-3 from Baseline to Week 12 (Change over 12 weeks)
Clinical Global Impressions - Improvement (CGI-I)
The degree of change of in condition from baseline will be assessed using the CGI-I scale. The CGI-I is a clinician-rated global measure of improvement scale used to assess the degree of symptom change in a patient relative to baseline condition. It consists of a 7-point scale as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse, such that lower scores are indicative of increased symptom improvement. Scores will be summarized by study arm using basic descriptive statistics.
Measured: Change in CGI-I from Baseline to Week 12 (Change over 12 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jun 2017
- Study start12 Apr 2019
- Primary completion9 Mar 2026
- Study completion30 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Autism Spectrum DisorderStudies of the same condition, open and under way.
- More trials run by Montefiore Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Phase 2, 12-week double-blind, randomized, placebo-controlled trial
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Montefiore Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- United States Department of Defense, GW Pharmaceuticals Ltd, Jazz Pharmaceuticals
- Responsible party
- Sponsor
- Investigators
- Eric Hollander, MD, Principal investigator, Montefiore Medical Center/Albert Einstein College of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03202303
- Sponsor's protocol ID
- 2017-8538
- Other IDs
- AR160104, G32379
- Status last verified
- Nov 2026
- First submitted
- 27 Jun 2017
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ferretti CJ, Cook BL, Mahant AM, Chu P, Zhao Y, Taylor BP, Herold BC, Hollander E. Cognitive inflexibility and immunome biomarkers in children with autism spectrum disorder. Neurosci Appl. 2024 May 4;3:104071. doi: 10.1016/j.nsa.2024.104071. eCollection 2024.
PubMed 40656115
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)
- ClinicalTrials.gov ID
- NCT03202303
- Acronym / sponsor ID
- 2017-8538
- Conditions
- Autism Spectrum Disorder
- Keywords
- Autism, Irritability, Cannabinoids
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Montefiore Medical CenterUniversity, hospital or other
- Collaborators
- United States Department of Defense, GW Pharmaceuticals Ltd, Jazz Pharmaceuticals
- Study start
- 12 Apr 2019 (actual)
- Primary completion
- 9 Mar 2026 (actual)
- Study completion
- 30 Jun 2026 (actual)
- First posted
- 28 Jun 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial aims to study the efficacy and safety of cannabidivarin (CBDV) in children with ASD.
Detailed description
There is a clear unmet need for new therapeutics to treat irritability in children with ASD that do not have the metabolic and weight adverse event profiles of the currently approved treatments. Cannabidivarin (CBDV) is a nonpsychoactive phytocannabinoid and a safe variant of Cannabidiol (CBD). It has no appreciable tetrahydrocannabinol (THC) [less than 0.01%], has been shown to have no impact on weight or metabolism, and improves both social and cognitive functioning in animal models of idiopathic and syndromal autism (Fragile X, Rett Syndrome, Angelman Syndrome). The CDC currently estimates 1 in 59 children have ASD. ASD is characterized by deficits in social communication, irritability, repetitive behaviors, impulsivity, temper tantrums, and high caregiver burden. Currently, the only FDA-approved medications for symptoms of ASD are aripiprazole and risperidone, both of which are indicated for irritability in pediatric ASD. These medications are effective but are associated with considerable side effects with long term treatment in this chronic developmental disorder, including weight gain, metabolic syndrome and the risk of type 2 diabetes, prolactin elevation and growth of breast tissue, extrapyramidal symptoms and the risk of tardive dyskinesia. The anticonvulsant divalproex sodium (valproate/VPA) also significantly reduces irritability and repetitive behaviors in individuals with ASD. Although VPA is efficacious for pediatric epilepsy and some symptoms of ASD, it also has significant side effects, including weight gain, sedation and nausea. CBDV, like VPA, is effective in the treatment of pediatric epilepsy, and ASD mouse models demonstrate potential mechanisms for treatment with CBDV, including potential therapeutic effects on repetitive behaviors, irritability, sociability, and quality of life, and the capacity to reduce inflammation. This study aims to examine the efficacy and safety of cannabidivarin (CBDV) with a primary aim of studying its effect on irritability in children with ASD.
STUDY DESIGN: This is a 12-week randomized, double-blind study of CBDV vs. placebo in 100 child and adolescent subjects aged 5 to 18 years with a diagnosis of ASD.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Phase 2, 12-week double-blind, randomized, placebo-controlled trial
| Arm | Type | Receives |
|---|---|---|
| Cannabidivarin (CBDV) | Experimental | Drug: CannabidivarinWeight-based dosing of 10 mg/kg/day of CBDV for 12 weeks |
| Matched Placebo | Placebo comparator | Drug: Matched PlaceboWeight-based dosing of 10 mg/kg/day of placebo for 12 weeks |
Who may qualify
- Ages
- 5 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (7 listed)
- Male or Female pediatric outpatients aged between and including ages 5 to 18. Diagnosis of Autism Spectrum Disorder (ASD) confirmed by the ADOS-2 and DSM-5 criteria.*During special circumstances (e.g. COVID-19 pandemic) where the ADOS-2 cannot be performed due to site restrictions (e.g. mandatory use of face masks), eligibility can be confirmed using the Autism Diagnostic Interview, Revised (ADI-R)
- Aberrant Behavior Checklist (ABC) - Irritability Subscale (ABC-I) score of 18 or greater at screening visit.
- Social Responsiveness Scale (SRS) score of 66T or higher at screening visit.
- Clinical Global Impression Scale - Severity (CGI-S) score of 4 or higher at screening.
- Stable pharmacologic, educational, behavioral and/or dietary interventions for 4 weeks prior to randomization and for the duration of the study.
Key exclusion criteria (13 listed)
- Exposure to any investigational agent in the 30 days prior to randomization.
- Prior chronic treatment with CBD, CBDV or an endocannabinoid treatment.
- Positive testing for THC or other drugs of abuse via urine testing at the screening visit or baseline visits upon repeat confirmation testing.
- Recent history of drug abuse including marijuana/cannabis use in the past 3 months.
- Diagnosis of a known genetic disorder (ie. Prader-Willi Syndrome, Angelman Syndrome etc.).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CannabidivarinAlso: CBDVWeight-based dosing of 10 mg/kg/day of CBDV | Drug | Cannabidivarin (CBDV) |
| Matched PlaceboAlso: PlaceboWeight-based dosing of 10 mg/kg/day of placebo | Drug | Matched Placebo |
Primary outcome
Aberrant Behavior Checklist-Irritability (ABC-I) Subscale
Time frame: Change from Baseline to Week 12 (Change over 12 weeks)
Change in aberrant behavior from baseline will be assessed using the irritability subscale of the ABC. The ABC is an informative rating instrument that was empirically derived by principal component analysis to measure behavior in those with developmental disability and autism spectrum disorder (ASD). The ABC-I will be completed by any adult who knows the patient well, such as a parent/caregiver. The ABC-I subscale consists of 15 items that address the presence of aggression, tantrums, and/or self-injury. Scores for each item on the subscale range from 0 (no problem at all) to 3 (problem is severe in degree), yielding an overall possible score for the subscale from 0-45, such that higher scores are indicative of increased severity of irritability. Scores will be summarized by study arm using basic descriptive statistics.
6 secondary outcomes
Repetitive Behavior Scale-Revised (RBS-R)
Time frame: Change in RBS-R from Baseline to Week 12 (Change over 12 weeks)
Montefiore Einstein Rigidity Scale-Revised (MERS-R)
Time frame: Change in MERS-R from Baseline to Week 12 (Change over 12 weeks)
Aberrant Behavior Checklist-Social Withdrawal (ABC-SW) Subscale
Time frame: Change in ABC-SW from Baseline to Week 12 (Change over 12 weeks)
Pediatric Quality of Life Inventory (PedsQL) Family Impact Module
Time frame: Change in PedsQL from Baseline to Week 12 (Change over 12 weeks)
Vineland Adaptive Behavior Scale, Third Edition (VABS-3)
Time frame: Change in VABS-3 from Baseline to Week 12 (Change over 12 weeks)
Clinical Global Impressions - Improvement (CGI-I)
Time frame: Change in CGI-I from Baseline to Week 12 (Change over 12 weeks)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Derived from this study: PubMed 40656115Ferretti CJ, Cook BL, Mahant AM, Chu P, Zhao Y, Taylor BP, Herold BC, Hollander E. Cognitive inflexibility and immunome biomarkers in children with autism spectrum disorder. Neurosci Appl. 2024 May 4;3:104071. doi: 10.1016/j.nsa.2024.104071. eCollection 2024.
- Individual participant dataSharing planned: No
Related trials for Autism Spectrum Disorder
RecruitingPhase 1
Cannabidiol (CBD) in Adults With ASD
Autism Spectrum Disorder
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Sensory-integration Therapy Verses Augumented Reality-based Training in ASD
Autism Spectrum Disorder
Recruiting
Cumulative and Booster Effects of Multisession Prefrontal tDCS in ASD Adolescents
Transcranial Direct Current Stimulation, Autistic Spectrum Disorder
Not yet recruiting
"Family Resilience And Mind-body Enhancement" (FRAME): A Randomised Controlled Trial
Autism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eric Hollander, MD principal investigator
Montefiore Medical Center/Albert Einstein College of Medicine
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Cannabidivarin in people with Autism Spectrum Disorder, run by Montefiore Medical Center at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Aberrant Behavior Checklist-Irritability (ABC-I) Subscale (time frame: Change from Baseline to Week 12 (Change over 12 weeks)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03202303, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.